Skip to main content

Long-term response after electrochemotherapy in patients with relapsed or refractory cutaneous melanoma


Treatment of early and multiple cutaneous unresectable recurrences is a major therapeutic problem with around 80% of patients relapsing within 5 years [1]. For lesions refractory to elective treatments, electrochemotherapy (ECT) involving electroporation combined with antineoplastic drug treatment appears to be a new potential option [2]. This study was undertaken to analyze the short- and long-term responses of lesions treated with ECT with intravenous injection of bleomycin in melanoma patients with in-transit disease or distant cutaneous metastases.

Materials and methods

Between January 2007 and September 2012, 60 patients with relapsed and refractory cutaneous melanoma metastases or in-transit disease underwent 100 courses of ECT with intravenous injection of bleomycin. Response to treatment was evaluated three months after ECT. A long-lasting response was defined as no cutaneous or in-transit relapse after a minimum of six months.


Three months after ECT, a complete response was observed in 29 patients (48.4%), a partial response in 23 patients (38.3%) and no change or progressive disease in 8 patients (13.3%). The objective response rate of all treated lesions was 86.6%. Thirteen patients (44.8% of complete responders) experienced a long-lasting response to ECT and were disease-free after a mean duration of follow-up of 27.5 months.


The favorable outcome obtained in the present study demonstrates that ECT is a reliable, and effective procedure that provides long-term benefit in terms of curative and palliative treatment for unresectable cutaneous lesions without adversely impacting the quality of life of patients [37].


  1. 1.

    Leon P, Daly J, Synnestvedt M, Schultz DJ, Elder DE, Clark WH: The prognostic implications of microscopic satellites in patients withclinical Stage I melanoma. ArchSurg. 1991, 126: 1461-68.

    CAS  Google Scholar 

  2. 2.

    Marty M, Garbay JM, Gehl J: Electrochemotherapy an easy, highly effective and safe treatment of cutaneous and subcutaneous metastases: results of ESOPE (European Standard Operating Procedures of Electrochemotherapy) study. Eur J Cancer. 2006, 4: 3-13.

    CAS  Article  Google Scholar 

  3. 3.

    Sersa G, Miklavcic D, Cemazar M, Rudolf Z, Pucihar G, Snoj M: Electrochemotherapy in treatment of tumors. Eur J SurgOncol. 2007, 34: 232-40.

    Article  Google Scholar 

  4. 4.

    Quaglino P, Mortera C, Osella-Abate S: Electrochemotherapy with intravenous bleomycin in the local treatment of skin melanoma metastases. Ann Surg Oncol. 2008, 15: 2215-22. 10.1245/s10434-008-9976-0.

    CAS  Article  PubMed  Google Scholar 

  5. 5.

    Sersa G, Stabuc B, Cemazar M, Miklavcic D, Rudolf Z: Electrochemotherapy with cisplatin: systemic antitumor effectiveness of cisplatin can be potentiated locally by the application of electric pulses in the treatment of malignant melanoma skin metastases. Melanoma Res. 2000, 10: 381-85. 10.1097/00008390-200008000-00010.

    CAS  Article  PubMed  Google Scholar 

  6. 6.

    Kaehler KC, Egberts F, Hauschild A: Electrochemotherapy in symptomatic melanoma skin metastases: intraindividual comparison with conventional surgery. Dermatol Surg. 2010, 36: 1200-02. 10.1111/j.1524-4725.2010.01608.x.

    CAS  Article  PubMed  Google Scholar 

  7. 7.

    Mozzillo N, Caracò C, Mori S: Use of neoadjuvantelectrochemotherapy to treat a large metastatic lesion of the cheek in a patient with melanoma. J Transl Med. 2012, 10: 131-10.1186/1479-5876-10-131.

    PubMed Central  Article  PubMed  Google Scholar 

Download references

Author information



Corresponding author

Correspondence to Ugo Marone.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Mozzillo, N., Caracò, C., Marone, U. et al. Long-term response after electrochemotherapy in patients with relapsed or refractory cutaneous melanoma. J Transl Med 12, P1 (2014).

Download citation


  • Melanoma
  • Intravenous Injection
  • Bleomycin
  • Melanoma Patient
  • Objective Response Rate